Proportion of participants losing ≥ 10 EDTRS letters · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression of geographic atrophy · adults with GA due to AMD
1 finding from 1 review
Advanced AMD · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in macular sensitivity · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with GA due to AMD
1 finding from 1 review
Change in BCVA from baseline to 24 months · adults with GA due to AMD
1 finding from 1 review
Proportion of participants losing ≥ 15 EDTRS letters · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in number of Demodex mites per 8 eyelashes at 4–6 weeks · Demodex blepharitis
1 finding from 1 review
Mean change in participant‐reported change in symptoms at 4–6 weeks · Demodex blepharitis
1 finding from 1 review
Visual acuity · Demodex blepharitis
1 finding from 1 review
Mean change in (or mean) number of cylindrical dandruff at 4–6 weeks · Demodex blepharitis
1 finding from 1 review
Proportion of participants with meibomian gland dysfunction at 4–6 weeks · Demodex blepharitis
1 finding from 1 review
Proportion of participants experiencing conjunctival injection (redness) at 4–6 weeks · Demodex blepharitis
1 finding from 1 review
Adverse events at 4‐6 weeks · Demodex blepharitis
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes dry eye symptoms, measured using the SPEED score at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
MD 0
Studies not reported
Very low
Incidence of adverse events at 3 months of · people with meibomian gland dysfunction
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Clinical signs—TBUT at 1 month (seconds) · people with meibomian gland dysfunction
IPL (with/without MGX) showed no clear difference in sodium fluorescein TBUT, measured in seconds, at 3 months of compared with sham or no treatment (with/without MGX) (low certainty).
1 finding from 1 review
MD 2.02
Studies not reported
Low
NIBUT, measured in seconds, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes NIBUT, measured in seconds, at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
MD 5.5
Studies not reported
Very low
Tear osmolarity, measured in mOsmol/L, at 3 months of · people with meibomian gland dysfunction
IPL (with/without MGX) showed no clear difference in tear osmolarity, measured in mOsmol/L, at 3 months of compared with sham or no treatment (with/without MGX) (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Meibomian gland orifice plugging, at 3 months of · people with meibomian gland dysfunction
It is very uncertain whether IPL (with/without MGX) changes meibomian gland orifice plugging, at 3 months of compared with sham or no treatment (with/without MGX) (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low